A multi-center phase Ib/II study of RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2 positive locally advanced muscle-invasive urothelial bladder cancer (Hope-03)
Latest Information Update: 12 Jul 2024
At a glance
- Drugs Disitamab vedotin (Primary) ; Tislelizumab (Primary)
- Indications Bladder cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms ChiECRCT20210564; Hope-03
Most Recent Events
- 12 Jul 2024 New trial record
- 04 Jun 2024 Preliminary Results(n=18) of this trial were presented at the 60th Annual Meeting of the American Society of Clinical Oncology